ATRI Stock Analysis
AT
Avoid
Based on Eyestock quantitative analysis, ATRI`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Atrion Corporation (Atrion) is engaged in the development and manufacture of products for medical applications. The Company's medical products primarily serve the fluid delivery, cardiovascular and ophthalmology markets. It has developed a variety of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in fields, such as anesthesia and oncology. Atrion's cardiovascular product, Myocardial Protection System (MPS3), is a technology used in open-heart surgery that delivers fluids and medications, mixes critical drugs, and controls temperature and pressure. Its ophthalmic products include specialized medical devices that disinfect contact lenses. Atrion also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. Its medical and non-medical products are manufactured at facilities in Florida, Alabama and Texas.